All In Biotech

Drug Trial Radar · NCT06249048

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

May 3, 2024

Primary completion

Jun 17, 2026

Study completion Jun 17, 2026

Sponsor

Lead sponsor
Strand Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Feb 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.

Conditions

  • Advanced Solid Tumor

Interventions

  • STX-001Biological

    STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection. Injections may be administered into multiple lesions according to protocol-defined procedures.

  • Keytruda®Biological

    Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and nature of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients with advanced solid tumors.Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).
  2. Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-001.Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • HonorHealth Research and Innovation Institute

    Scottsdale, Arizona

  • NextGen Oncology

    Beverly Hills, California

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah

  • Melanoma Institute Australia

    Wollstonecraft, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.